Amgen (AMGN)

Add a New Bulls Reason Company: Amgen (AMGN) Current price: Headline: (100 character max) Analysis: Cancel 88% agree 9 votes edit Denosumab is a breakthrough in a large osteoperosis market Top Contributor: Michael Sha | Created when NASDAQ:AMGN was $55.31 | Edit | History Amgen's Denosumab is a breakthrough drug in a large ($7B+) and growing market - osteoperosis. Its once-every-six-month formulation will help solve the compliance problems in the osteoporosis market and save insurance companies money because they will have to pay for fewer costly hip fractures. (100 character max) Cancel 100% agree 3 votes edit Amgen's longer-acting Aranesp has been steadily taking market share Top Contributor: Michael Sha | Created when NASDAQ:AMGN was $55.31 | Edit | History Amgen's longer-acting Aranesp has been steadily taking market share away from Johnson and Johnson's Procrit, and there are greater inroads on the horizon. (100 character max) Cancel 66% agree 3 votes edit Amgen is cheap Created when NASDAQ:AMGN was $53.63 | Edit | History Amgen is cheap - a stock price in the fifties corresponds to a foward P/E ratio of around 12, meaning that a lot of the risks to this stock are already priced in. (100 character max) Cancel

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.